Greg Hoffman serves as the Chief Scientific Officer at Deep Genomics, where he leverages his extensive expertise in biophysics and cell biology to spearhead groundbreaking initiatives in the realm of RNA biology and oligo-based therapeutics. With over a decade of industry experience, Greg has cultivated...
Greg Hoffman serves as the Chief Scientific Officer at Deep Genomics, where he leverages his extensive expertise in biophysics and cell biology to spearhead groundbreaking initiatives in the realm of RNA biology and oligo-based therapeutics. With over a decade of industry experience, Greg has cultivated a deep understanding of genomic screening and early target discovery, positioning him at the forefront of innovative drug development strategies. His leadership is instrumental in guiding interdisciplinary teams of machine learning and drug development scientists, who are dedicated to decoding the complexities of RNA biology.
At Deep Genomics, Greg is currently overseeing several key projects aimed at harnessing the power of artificial intelligence to accelerate the drug discovery process. By integrating high-throughput screening techniques with advanced machine learning algorithms, his team is able to identify novel therapeutic targets more efficiently than traditional methods allow. This approach not only enhances the likelihood of successful clinical translation but also significantly reduces the time and resources typically required in drug development.
Greg's background as a trained biophysicist and cell biologist informs his innovative approach to studying the molecular basis of diseases. His proficiency in assay development and protein expression is critical in the design of oligo-based therapeutics, which hold promise for treating a range of genetic disorders. As he continues to push the boundaries of biotechnology, Greg remains committed to fostering collaboration with partners across the industry, ensuring that the insights gained from their AI Foundation Models translate into tangible clinical outcomes. Through his visionary leadership, Deep Genomics is poised to redefine the landscape of gene therapy and precision medicine.
